Key Details
The IIMA Healthcare Summit 2026 signalled the Government’s priorities for expanding AI use across pharmaceuticals and healthcare. No new funding programme was announced, although support for eligible start-ups is under consideration.
Area | Update |
|---|---|
Startup assistance | Government is working towards support for eligible start-ups’ software-licensing and operating costs |
AI applications | Drug discovery, clinical trials, personalised medicine, disease screening and clinical decision support |
Centres of Excellence | Established at AIIMS New Delhi, PGIMER Chandigarh and AIIMS Rishikesh |
Digital health base | More than 96 crore ABHA IDs and over 1,000 crore digitally linked health records |
Existing public support | ₹5,000 crore PRIP Scheme and ₹10,000 crore Biopharma SHAKTI mission |
Deployment principle | AI should complement, not replace, human clinical judgement |
Support for Startups Is Being Considered
The Department of Pharmaceuticals said start-ups, particularly in Bengaluru and Hyderabad, are using AI to accelerate the identification and shortlisting of potential drug candidates.
Officials identified finance, software licences, computing resources and specialised talent as major constraints. The Government is working towards providing support for eligible start-ups’ licensing and operating costs, but the release does not specify the amount, eligibility conditions or timeline.
AI Is Already Entering Healthcare Delivery
The Summit highlighted AI-enabled applications for the early detection of tuberculosis and diabetic retinopathy, as well as clinical decision support through eSanjeevani. The Government said the telemedicine platform has benefited more than 20 crore patients.
The Ayushman Bharat Digital Mission is creating the wider digital foundation through interoperable health records, facilities and professional registries. AIKosh is intended to expand access to datasets, models and technical tools.
Officials also called for healthcare and genetic data to be made available to Indian innovators with appropriate safeguards.
Research Policy Is Moving Beyond Generic Medicines
The Promotion of Research and Innovation in Pharma-MedTech Sector Scheme, with an outlay of ₹5,000 crore, supports pharmaceutical research and industry–academia collaboration.
The ₹10,000 crore Biopharma SHAKTI mission focuses on biologics, biosimilars, skilled manpower, regulation and clinical-trial capabilities. Together with the IndiaAI and National Biopharma Missions, these initiatives provide the policy base for expanding domestic drug research and healthcare innovation.
At the Summit, the Government described this transition as moving India from the “Pharmacy of the World” to the “Laboratory of the World.”
Policy Relevance
Startup support needs defined selection criteria. Assistance should identify which costs and stages of AI-led research are eligible and what evidence of progress recipients must demonstrate.
Access to data cannot be separated from safeguards. Health and genetic datasets require clear rules governing consent, privacy, security and authorised use.
Clinical evidence must precede large-scale adoption. Moving from pilots to population-level use requires testing across Indian patients, institutions and healthcare settings.
Responsibility must remain identifiable. Clinicians and healthcare institutions should retain accountability when AI informs screening, diagnosis or treatment decisions.
Relevant Question for Policy Stakeholders: What clinical evidence and data safeguards should be mandatory before an AI-healthcare application moves from a pilot to population-scale use?
Follow the Full Update Here: IIMA Healthcare Summit 2026 Deliberates on India’s AI-Driven Healthcare Vision
Source link
